19237-84-4, 86126-06-9; 19216-56-9; 98319-26-7 Prazosin HCl AKSci J10591
 
 
Loading Please Wait...
  J10591    AKSci Reference Standard
Prazosin HCl, >98% (HPLC)
 
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine Hydrochloride
Furazosin hydrochloride
IDENTITY
CAS Number:19237-84-4, 86126-06-9; 19216-56-9; 98319-26-7
MDL Number:MFCD00058177
MF:C19H22ClN5O4
MW:419.86
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:>98% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:273-282°C
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:Soluble to 25 mM in DMSO and to 5 mM in ethanol
Application(s):alpha-1-Adrenergic receptor antagonist
Form:HCl salt

REVIEW
 Prazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

REFERENCES
[1]Bawaskar HS, Bawaskar PH: Utility of scorpion antivenin vs prazosin in the management of severe Mesobuthus tamulus (Indian red scorpion) envenoming at rural setting. J Assoc Physicians India. 2007 Jan;55:14-21.
[2] Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404.
[3] Hiraoka Y, Taniguchi T, Tanaka T, Okada K, Kanamaru H, Muramatsu I: Pharmacological characterization of unique prazosin-binding sites in human kidney. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jul;368(1):49-56. Epub 2003 Jun 25.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H302; H315; H319; H335; H361

Precautionary Statements
P201; P202; P261; P264; P270; P271; P280; P301+P312; P302+P352; P304+P340; P305+P351+P338; P308+P313; P321; P330; P332+P313; P337+P313; P362; P403+P233; P405; P501

Current as of March 26, 2023

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS Request COA

⚠️
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.


CATEGORIES
 APIs and Bioactives > Alpha Blockers


PubChem